Truist lowered the firm’s price target on Treace Medical (TMCI) to $9.50 from $10 and keeps a Hold rating on the shares after its recent ...

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Treace Medical Concepts (TMCI – Research ...

Those following along with Treace Medical Concepts, Inc. (NASDAQ:TMCI) will no doubt be intrigued by the recent purchase of shares by John Treace, CEO, Founder & Director of the company, who spent a ...

Rhumbline Advisers raised its stake in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI – Free Report) by 2.0% in the fourth quarter, according to the company in its most recent 13F filing with ...

Treace Medical Concepts, Inc. (NASDAQ:TMCI – Get Free Report) has been given a consensus recommendation of “Hold” by the seven analysts that are covering the company, MarketBeat reports. Five ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $10.22, a high estimate of $14.50, ...

Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Welcome to the Treace Medical Concepts Fourth Quarter 2024 ...

Looking ahead, revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 7.8% growth forecast ...

Treace Medical Concepts Inc (TMCI) reports a 10.4% revenue increase and unveils new products, setting the stage for future growth despite a slight dip in gross margin.

Treace, CEO, Founder and Board Member of Treace. "We are excited to enter 2025 with our expanded bunion portfolio and look forward to delivering additional innovations to address the evolving needs of ...

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 66.67% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the ...

PONTE VEDRA, Fla. (AP) — PONTE VEDRA, Fla. (AP) — Treace Medical Concepts Inc. (TMCI) on Thursday reported a loss of $501,000 in its fourth quarter. The Ponte Vedra, Florida-based company said ...